3 Secrets to Minimizing High-Cost Products on Your Formulary

An important part of limiting spend is helping members avoid high cost products when equally effective generic alternatives exist.

If you’re a plan sponsor, chances are that you have your hands full working to keep pharmacy costs manageable for your organization and your employees. With over 20,000 prescription drugs currently approved for marketing by the FDA, deciding which drugs to cover can be a challenge.1 Unfortunately, a number of market events can lead to scenarios where even small shifts in utilization can result in large cost increases for plans. Having a PBM partner with the tools and experience necessary to address these scenarios when they occur is imperative for every plan sponsor.

Here are three examples of such market events and how we responded to keep plan costs low.

Secret #1: SET THE STAGE FOR UPCOMING GENERICs

Generic medications are chemically identical to their brand-name counterparts, but can offer significant savings. However, it can be difficult for plan sponsors to take advantage of the launch of a new generic if members are already using a number of similar products. In the case of Lyrica®, a nerve pain medication that can also be used to treat seizures, an extended release formulation (Lyrica® CR) was launched in 2018, a year before the generic alternative became available. Allowing members to switch to the new formulation in the short term would make it more costly and difficult to move them to the generic later. By keeping Lyrica® CR off the formulary and having almost no utilization at the time the generic launched, plan sponsors were better able to take advantage of the cost-savings associated with the generic when it became available in 2019.

SECRET #2: Protect Your Plan from “New” Products Identical to Generics

Some high-cost products claim to be new, but differ only minimally from existing generics, such as in dosage strength. For instance, Aplezin™, an extended release bupropion product, can cost over $1,000 per claim. In contrast, other generic extended release bupropion products are available for less than $20 per month. In these cases, a handful of members using the more expensive formulation can have a major impact on plan spend. A lowest-net-cost formulary strategy prevents this by covering only the less-expensive, but clinically equivalent alternative.

SEcret #3: Block Unnecessarily Repackaged Vitamins

A popular practice in recent years is packaging several common vitamins together into a high-cost “pack.” Far more expensive than separately packaged vitamins, these can drive up plan costs by thousands of dollars per claim. A proactive approach to blocking these is important, as some pharmacies will use them to generate additional revenue at the plan’s expense. Plan sponsors can shield themselves from these unnecessary costs by identifying these products and excluding them from their formularies.

Want to learn more about ways to reduce your costs? Download our 2019 Drug Trend Report today! It’s loaded with cost management strategies that can help get your Rx benefits headed in the right direction.

Fact Sheet: FDA at a Glance. U.S. Food and Drug Administration. https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance. Updated October 18, 2019. Accessed June 3, 2020.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Navigating with a trusted partner

Now Available: 9th Annual Drug Trend Report

Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.

Related blogs

Navigating Healthcare and Improving Outcomes

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients.  …

Navigating the Drug Supply Chain: What You Need to Know

Navigating the Drug Supply Chain: What You Need to Know

Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

previous arrow
next arrow